Literature DB >> 2360821

Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin.

S L Barriere1, D H Catlin, P L Orlando, A Noe, R W Frost.   

Abstract

Healthy subjects were given single intravenous doses of ciprofloxacin, azlocillin, and the two drugs simultaneously on separate occasions. High-pressure liquid chromatographic analysis was used to assay the concentrations of both drugs in serum and urine. Pharmacokinetic parameters were calculated by noncompartmental methods. The total body (CL), renal (CLR), and nonrenal (CLNR) clearances; steady-state volume of distribution (Vss); and fractional urinary excretion of ciprofloxacin were all markedly decreased with the simultaneous administration of azlocillin. The disposition of azlocillin was unchanged when it was given with ciprofloxacin compared to when it was given alone. The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively. This interaction resulted in significantly higher and more prolonged concentrations of ciprofloxacin in serum, which may be beneficial in the treatment of serious gram-negative bacterial infections, but it could also produce greater toxicity or result in more pronounced effects on oxidative drug metabolism of other medications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360821      PMCID: PMC171699          DOI: 10.1128/AAC.34.5.823

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

Authors:  D M Bamberger; L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

2.  In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model.

Authors:  L R Peterson; J A Moody; C E Fasching; D N Gerding
Journal:  Diagn Microbiol Infect Dis       Date:  1987-06       Impact factor: 2.803

3.  Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.

Authors:  M Johnson; P Miniter; V T Andriole
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

4.  Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model.

Authors:  S H Zinner; M N Dudley
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

5.  Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.

Authors:  L C Rodondi; J F Flaherty; P Schoenfeld; S L Barriere; J G Gambertoglio
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875

Review 6.  The acylampicillins: mezlocillin, piperacillin, and azlocillin.

Authors:  G L Drusano; S C Schimpff; W L Hewitt
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

7.  Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.

Authors:  D B Webb; D E Roberts; J D Williams; A W Asscher
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

Review 8.  Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.

Authors:  M LeBel
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

9.  Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.

Authors:  D Kampf; K Borner; M Möller; M Kessel
Journal:  Clin Pharmacol Ther       Date:  1984-02       Impact factor: 6.875

  9 in total
  8 in total

1.  Effect of several antimicrobial agents on ciprofloxacin uptake by human neutrophils.

Authors:  I García; A Pascual; E J Perea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

2.  Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates.

Authors:  S Dautrey; K Felice; A Petiet; B Lacour; C Carbon; R Farinotti
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.

Authors:  Larry A Bauer; Douglas J Black; Jennifer S Lill; Julie Garrison; Vidmantas A Raisys; Thomas M Hooton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.

Authors:  M E Klepser; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 6.  Pharmacokinetics of quinolones: newer aspects.

Authors:  J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

7.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

Review 8.  Do we need an intravenous fluoroquinolone?

Authors:  D S Maddix; L Warner
Journal:  West J Med       Date:  1992-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.